Research Grade Anti-Human CD47/MER6 (HMPL-a83) (HC359166)

Datasheet Share product Copy info

Price(USD): $

Spec:

100ug
1mg

Number:

Overview
Images
References
Datasheet

Overview

Catalog No.	HC359166
Description	Anti-Human CD47/MER6 (HMPL-a83) (HC359166) is a research-grade recombinant antibody targeting CD47. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG
Clone ID	HMPL-a83
Expression system	Mammalian Cells
Clonality	Monoclonal
Target	Leukocyte surface antigen CD47, CD47, Antigenic surface determinant protein OA3, IAP, Integrin-associated protein, Protein MER6, MER6
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	Q08722
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names	HMPL-a83, HMPLa83, HMPLa83
Background	Leukocyte surface antigen CD47 (MER6) is a ~35 kDa protein. Adhesive protein that mediates cell-to-cell interactions. Acts as a receptor for thrombospondin THBS1 and as modulator of integrin signaling through the activation of heterotrimeric G proteins. Involved in signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, cellular self-renewal, and immunoregulation. Plays a role in modulating pulmonary endothelin EDN1 signaling. Modulates nitrous oxide (NO) signaling, in response to THBS1, hence playing a role as a pressor agent, supporting blood pressure. CD47 is the therapeutic target of magrolimab (clinical). 1. Latour, S. et al. (2001) Journal of immunology (Baltimore, Md. : 1950) 167, 2547-54. PMID: 11509594 2. Piccio, L. et al. (2005) Blood 105, 2421-7. PMID: 15383453 3. Isenberg, JS. et al. (2009) The Journal of biological chemistry 284, 1116-25. PMID: 19004835 4. Lindberg, FP. et al. (1993) The Journal of cell biology 123, 485-96. PMID: 7691831 5. Gao, AG. et al. (1996) The Journal of biological chemistry 271, 21-4. PMID: 8550562 6. Rogers, NM. et al. (2017) Cardiovascular research 113, 15-29. PMID: 27742621 7. Ghimire, K. et al. (2020) Cells 9. PMID: 32679764
Note	For research use only. Not suitable for clinical or therapeutic use.